Evidence map›Paper›PMID 38291388›Full record

ArticleBMC gastroenterology2024

Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis.

Florian F Hildenbrand, Barbara Illi, Stefanie von Felten, Jacqueline Bachofner, Joanna Gawinecka, Arnold von Eckardstein, Beat Müllhaupt, Joachim C Mertens, Sena Blümel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Florian F HildenbrandDivision of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Barbara IlliDivision of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Stefanie von FeltenDepartment of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Jacqueline BachofnerDivision of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Joanna GawineckaInstitute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Arnold von EckardsteinInstitute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Beat MüllhauptDivision of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Joachim C MertensCenter of Gastroenterology, Klinik Hirslanden, Zurich, Switzerland.
Sena BlümelDivision of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. sena.bluemel@usz.ch.
University of Zurich · CHUniversity Hospital of Zurich · CHKlinik Hirslanden · CH

Funding

Novartis Foundation 23A064Universität Zürich Walter and Gertrud Siegenthaler Fellowship
6 · The paper itself

Abstract

BACKGROUND &

aimsWith the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a serum biomarker for fibrotic processes. The aim of this study was to evaluate sST2 as marker for liver fibrosis in patients successfully treated for chronic hepatitis C.

methods424 patients from the Swiss Hepatitis C Cohort Study were screened for inclusion in this post-hoc cohort study. Inclusion criteria were sustained virological response (SVR), available elastography (VCTE) and serum samples for biomarker analysis before and after treatment. For the validation of sST2, values were compared to VCTE, FIB-4 and APRI using Spearman's correlation and AUROC analyses.

resultsData of 164 subjects were finally analyzed. Median sST2 values slightly increased with VCTE-derived fibrosis stages and remained stable after reaching SVR within the respective fibrosis stage, suggesting that sST2 is not influenced by liver inflammation. However, correlation of sST2 pre- and post-treatment with VCTE was fair (Spearman's rho = 0.39 and rho = 0.36). The area under the curve (AUROC) for sST2 in detecting VCTE-defined F4 fibrosis (vs. F0-F3) before therapy was 0.74 (95%CI 0.65-0.83), and 0.67(95%CI 0.56-0.78) for the discrimination of F3/F4 fibrosis vs. F0-F2. Adding sST2 to either APRI or FIB-4, respectively, increased diagnostic performance of both tests.

conclusionssST2 can potentially identify patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.

Indexed as

Elasticity Imaging TechniquesHepatitis C, ChronicAspartate AminotransferasesBiomarkersCohort StudiesHumansLiverLiver CirrhosisAspartate AminotransferasesBiomarkersCK-18ElastographyFIB-4HCVLiver fibrosissST2

Identifiers

PMID38291388
PMCPMC10825988
OpenAlexW4391360879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.